Quezada SA - Search Results

1

Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.

Peggs KS, Quezada SA, Allison JP. Peggs KS, et al. Among authors: quezada sa. Immunol Rev. 2008 Aug;224:141-65. doi: 10.1111/j.1600-065X.2008.00649.x. Immunol Rev. 2008. PMID: 18759925 Review.

2

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.

Peggs KS, Quezada SA, Korman AJ, Allison JP. Peggs KS, et al. Among authors: quezada sa. Curr Opin Immunol. 2006 Apr;18(2):206-13. doi: 10.1016/j.coi.2006.01.011. Epub 2006 Feb 7. Curr Opin Immunol. 2006. PMID: 16464564 Review.

3

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.

Quezada SA, Peggs KS, Curran MA, Allison JP. Quezada SA, et al. J Clin Invest. 2006 Jul;116(7):1935-45. doi: 10.1172/JCI27745. Epub 2006 Jun 15. J Clin Invest. 2006. PMID: 16778987 Free PMC article.

4

Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma.

Quezada SA, Peggs KS, Simpson TR, Shen Y, Littman DR, Allison JP. Quezada SA, et al. J Exp Med. 2008 Sep 1;205(9):2125-38. doi: 10.1084/jem.20080099. Epub 2008 Aug 25. J Exp Med. 2008. PMID: 18725522 Free PMC article.

5

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.

Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Peggs KS, et al. Among authors: quezada sa. J Exp Med. 2009 Aug 3;206(8):1717-25. doi: 10.1084/jem.20082492. Epub 2009 Jul 6. J Exp Med. 2009. PMID: 19581407 Free PMC article.

6

Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists.

Peggs KS, Quezada SA, Allison JP. Peggs KS, et al. Among authors: quezada sa. Clin Exp Immunol. 2009 Jul;157(1):9-19. doi: 10.1111/j.1365-2249.2009.03912.x. Epub 2009 Feb 18. Clin Exp Immunol. 2009. PMID: 19659765 Free PMC article. Review.

7

Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma.

Peggs KS, Quezada SA. Peggs KS, et al. Among authors: quezada sa. Expert Rev Anticancer Ther. 2010 Nov;10(11):1697-701. doi: 10.1586/era.10.144. Expert Rev Anticancer Ther. 2010. PMID: 21080797 Review.

8

Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.

Quezada SA, Peggs KS, Simpson TR, Allison JP. Quezada SA, et al. Immunol Rev. 2011 May;241(1):104-18. doi: 10.1111/j.1600-065X.2011.01007.x. Immunol Rev. 2011. PMID: 21488893 Free PMC article. Review.

9

Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer.

Quezada SA, Peggs KS. Quezada SA, et al. Br J Cancer. 2013 Apr 30;108(8):1560-5. doi: 10.1038/bjc.2013.117. Epub 2013 Mar 19. Br J Cancer. 2013. PMID: 23511566 Free PMC article.

10

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.

Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA. Simpson TR, et al. Among authors: quezada sa. J Exp Med. 2013 Aug 26;210(9):1695-710. doi: 10.1084/jem.20130579. Epub 2013 Jul 29. J Exp Med. 2013. PMID: 23897981 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results